Clinical trials: Carcinomas
Biliary Tract Cancer
Molecular Profiling of Advanced Biliary Tract Cancers
Biliary tract cancer (BTC) accounts for <1% of all cancers, but remains a highly fatal malignancy. Surgical resection is the only hope for cure, but most patients present with advanced disease when curative-intent surgery is not…
- Trial name
- COMPASS-B-MUHC (NCT04318834)
- Testing
- Tumour and germline molecular profiling
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Adult Solid Neoplasm, Peritoneal Carcinomatosis
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with radiation therapy in treating patients with advanced solid malignancies (abnormal cells divide without control and can invade nearby…
- Conditions
- Adult Solid Neoplasm, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01264432
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Prospective Collection of Samples for Urothelial Cancer of Bladder
ProCSUCaB (Prospective Collection of Samples for Urothelial Cancer of Bladder) is a monocentric, non-interventional, prospective registry that will recruit newly diagnosed intermediate- and high-risk NMIBC patients in a tertiary…
- Trial name
- ProCSUCaB (NCT04167332)
- Volunteers
- 630 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
This research trial studies chitinase 3-like 1 (cartilage glycoprotein-39) (YKL-40) in serum samples from patients with newly diagnosed stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer…
- Conditions
- Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT00899093
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 131 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Gynecologic Oncology Group
Thyroid Gland Medullary Carcinoma
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
This trial develops and studies how well a patient decision aid works in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active cancer monitoring for patients with medullary…
- Trial name
- NCT03892993
- Testing
- Decision Aid, Questionnaire Administration
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Cholecystitis, Acute, Pancreas Cancer, Duct Cell Adenocarcinoma
Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation
This prospective single-center study was designed by the investigators to evaluate the feasibility, safety, and efficacy of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) performed under endoscopist-directed…
- Conditions
- Cholecystitis, Acute, Pancreas Cancer, Duct Cell Adenocarcinoma, Cholangiocarcinoma
- Trial name
- NCT07704021
- Testing
- Sedation
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Total/Subtotal Colectomy in Ovarian Cancer
The purpose of this study is to evaluate the safety and one year disease-free survival of total or subtotal colectomy and proctocolectomy in stage IIIc and stage IV epithelial ovarian, fallopian tube, and primary peritoneal…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Secondary Malignant Neoplasm of Large Intestine
- Trial name
- NCT02595021
- Testing
- Total or Subtotal Colectomy, Other Bowel Resection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Nasopharyngeal Carcinoma (NPC)
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
In order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial.
- Trial name
- NCT07188584
- Testing
- Reduced-Target Radiotherapy, Conventional Full-Target Radiotherapy
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Ming-Yuan Chen
Epithelial Ovarian Cancer, Ovarian Cancer
89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related death in women, with approximately 320,000 new cases and 200,000 deaths annually worldwide, and its incidence is rising.
- Trial name
- NCT07790939
- Testing
- 89Zr-DFO-Mirvetuximab PET/CT
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Barrett Esophagus, Esophageal Cancer
EsophaCap for the Detection of Early Esophageal Carcinoma
This study is to identify potential biomarkers for the early detection of Barrett's Esophagus, esophageal carcinoma (both adenocarcinoma and squamous cell carcinoma), and gastric cancer via sponge cytology.
- Conditions
- Barrett Esophagus, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT04214119
- Where
- 2 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.
This study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to…
- Trial name
- NCT06772428
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Atezolizumab plus bevacizumab is the first-line treatment for patients with advanced hepatocellular carcinoma. However, the prognosis for high-risk hepatocellular carcinoma is still poor, with a median overall survival of 7.6…
- Trial name
- NCT05886465
- Testing
- Atezolizumab, Bevacizumab, HAIC with FOLFOX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Stage IV Lung Adenocarcinoma
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer.
- Trial name
- NCT02120807
- Testing
- Certolizumab, cisplatin, pemetrexed
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC.
- Trial name
- NCT04109092
- Testing
- E7766
- Where
- 9 sites in United States
- Sponsor
- Eisai Inc.
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Pancreatic Carcinoma
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.
- Trial name
- NCT05634564
- Testing
- Tislelizumab, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 62 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.